Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:6/3/2010

of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
2. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
4. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
5. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
6. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
7. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
8. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
9. Sangamo Announces Pricing of Public Offering of Common Stock
10. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
11. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015  23andMe, Inc., the leading personal genetics company, ... Study in collaboration with Pfizer Inc. The companies ... more commonly known as lupus, into the study to ... is also in collaboration with the Lupus Research Institute, ... Approximately 1.5 million people in the U.S. ...
(Date:5/5/2015)... Mass. , May 5, 2015 Psyche ... strategic alliance which offers a first-of-its-kind platform that helps ... access to lab results, transforms the way patients engage ... Luminate Health provides a HIPAA-compliant digital ... to access, manage, and understand their lab results, and ...
(Date:5/5/2015)... , May 5, 2015 Reprints Desk, Inc., ... providing on-demand access to scientific, technical and medical (STM) ... the Association of Southeastern Research Libraries (ASERL) . ... libraries located across 11 southeastern states. Founded in 1956, ... collaborative programs to address the continually changing needs of ...
(Date:5/5/2015)... 05, 2015 Franz Inc ., the ... announced that its flagship product, AllegroGraph, has been named a ... Market Update report. AllegroGraph is a high performance ... industry standards. Graph databases are skyrocketing in popularity and have ... a recent DBMS ranking by DB-Engines. , “We ...
Breaking Biology Technology:23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... ,, HARBIN, China , ... One Medical,Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter drugs in, the People,s ... its Tian Long,Pharmaceutical Company ("Tian Long") subsidiary successfully ...
... May 27 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services,Holdings Limited ("Concord ... the largest network of radiotherapy and diagnostic imaging centers,in China ... March 31, 2010 (1). , , First ... in the first quarter of 2010 were RMB76.2 million, ...
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Concord Medical Announces First Quarter 2010 Financial Results 2Concord Medical Announces First Quarter 2010 Financial Results 3Concord Medical Announces First Quarter 2010 Financial Results 4Concord Medical Announces First Quarter 2010 Financial Results 5Concord Medical Announces First Quarter 2010 Financial Results 6Concord Medical Announces First Quarter 2010 Financial Results 7Concord Medical Announces First Quarter 2010 Financial Results 8Concord Medical Announces First Quarter 2010 Financial Results 9Concord Medical Announces First Quarter 2010 Financial Results 10Concord Medical Announces First Quarter 2010 Financial Results 11Concord Medical Announces First Quarter 2010 Financial Results 12Concord Medical Announces First Quarter 2010 Financial Results 13Concord Medical Announces First Quarter 2010 Financial Results 14Concord Medical Announces First Quarter 2010 Financial Results 15CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... This release is available in French . ... of Medicine and the CHUQ Research Center have proven that ... Duchenne muscular dystrophy. The team, led by Professor Jacques P. ... published today in the online version of the scientific journal ...
... Program will feature new study results from the conference ... their presentation at ELCC): Making EGFR ... radiation in patients with locally advanced lung cancer: first ... lung cancer in organ transplant recipients, Hyperfractionated radiotherapy for ...
... PITTSBURGH, April 15 Certain genetic variations may be ... periodontitis, according to two recently published papers by researchers ... and their collaborators. Alexandre R. Vieira, D.D. S., ... professor of oral biology, and his colleagues at the ...
Cached Biology News:Researchers prove the gene responsible for Duchenne muscular dystrophy can be repaired 22nd European Lung Cancer Conference 22nd European Lung Cancer Conference 3Pitt Dental School researchers find susceptibility for caries, gum disease in genes 2
... is an antibody-mediated hot-start DNA ... and real-time PCR applications. The ... concentration of 5 units per ... polymerase, 1.25 ml 10x PCR ...
hnRNP U (H-94)...
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
... Perhaps sheer in-house demand is causing ... your precious antibody. This can cause unwanted ... Receive royalties for your hard ... and let us build it up,and market ...
Biology Products: